Researchers unveiled a genetic editing method that uses small nuclear RNAs instead of CRISPR. This approach produced fewer ...

Alumnus’s Owaves app helps people make the best of their natural body clock.

By upregulating the expression of the lone functioning copy of SCN2A, scientists addressed deficient brain signaling and reduced seizures.

CRISPR Therapeutics (SRSP) stock gains as the company gets a new Overweight rating from J.P. Morgan thanks to its therapeutic ...

Genetic editing holds promise to treat incurable diseases, but the most popular method - CRISPR - sometimes does more harm ...

Fintel reports that on September 18, 2025, JP Morgan initiated coverage of CRISPR Therapeutics (NasdaqGM:CRSP) with a Overweight recommendation. Analyst Price Forecast Suggests 37.35% Upside As of ...

Forget the glorious successes of past breakthroughs—the real justification for research investment is what we get for our ...

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $59.07, moving -3.46% from the previous trading session. The stock trailed the S&P 500, which registered a daily loss of 0.1%.

CRISPR Therapeutics AG is a long-term buy despite slow Casgevy uptake. Click for my updated look at CRSP earnings and the ...

When brain development gets off to a bad start, the consequences are lifelong. One example is a condition called SCN2A ...

A genome-editing technique known as prime editing holds potential for treating many diseases by transforming faulty genes into functional ones. However, the process carries a small chance of inserting ...